Mumbai: Ahmedabad-based Zydus Lifesciences is evaluating acquisition of a majority stake in US-based Ardelyx Inc., with the deal likely to be valued at $2.2–2.5 billion, two people aware of the development told Mint . The proposed transaction would be funded through a ₹5,000-crore equity raise via a qualified institutional placement (QIP) and internal cash accruals, the people said. If concluded, the deal would significantly accelerate Zydus’s push into global innovative medicine, an avenue that is attracti ...